Anpario (LSE:ANP) reported revenue of £24.3 million for the six months ended 30 June 2026, an increase of 7% from the prior-year period, while adjusted EBITDA rose 22% to £5.0 million.
Profit before tax increased 11%, and the animal feed additives manufacturer raised its interim dividend. The company attributed the earnings performance in part to pricing and lower underlying administrative costs.
Sales from Anpario’s key brands, which account for almost 80% of group revenue, increased 17% and reached a record level during the period.
Regional growth was led by India, the Middle East and Africa, alongside the Americas, which is now Anpario’s largest market. The company said its acquisition of Bio-Vet and the integration of the commercial teams contributed to sales growth in the United States and provided additional opportunities to sell products across the combined customer base.
Revenue in Asia declined 9%, primarily reflecting lower demand for mycotoxin binder products. Anpario attributed the decrease to economic conditions in the region and the impact of the Iran conflict.
The company continues to increase its focus on higher-value feed additives and plans to rebrand Bio-Vet under the Anpario name.
More about Anpario
Anpario plc is a UK-listed manufacturer of animal feed additives focused on animal health, nutrition and biosecurity.
Its product portfolio includes Orego-Stim, Optomega, pHorce, Mastercube and the Bio-Vet range. The company sells through direct operations and distribution channels across markets including the Americas, India, the Middle East, Africa and Asia.
Anpario’s acquisition of Bio-Vet expanded its activities in ruminant nutrition, including in the United States.
Leave a Reply